India’s Aurobindo Pharma will acquire the commercial operations and certain supporting infrastructure of Canadian pharmaceutical firm Apotex International in five European countries for $86.5 million.
Aurobindo expects to acquire commercial infrastructure including experienced personnel, products, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium.
The acquisition will help Aurobindo expand in eastern Europe and diversify its European product portfolio by adding over 200 generics and more than 80 over-the-counter products. According to the drugmaker, the deal will make Aurobindo one of the top 15 generic drug companies in Poland and the Czech Republic, a leading OTC company by volume in the Netherlands, and among the top five brands in retail generics market in Belgium.
Read the press release